BCL2 and neoplasm: Chidamide has been reported to exert its function mainly by upregulating the post-translational acetylation status of histones and non-histone proteins, which increases expression of various genes associated with the growth and survival of tumor cells, decreases the expression of Bcl-2 family and other pro-survival proteins, and upregulates some molecular markers recognized by immune cells and other chemotherapy drugs [44–46].